- Home
- KLRS vs FLL Comparison
KLRS vs FLL Comparison
Compare KLRS & FLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KLRS | FLL |
|---|---|---|
| Founded | 2019 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Hotels/Resorts |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 50.9M |
| IPO Year | 2020 | 2014 |
Fundamental Metrics
Financial Performance| Metric | KLRS | FLL |
|---|---|---|
| Price | $1.55 | $0.53 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 8 | 4 |
| Target Price | ★ $16.33 | $1.56 |
| AVG Volume (30 Days) | 70.4K | ★ 431.8K |
| Earning Date | 11-10-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 75.70 | 3.45 |
| EPS | N/A | ★ N/A |
| Revenue | $165,000.00 | ★ $302,376,000.00 |
| Revenue This Year | N/A | $3.53 |
| Revenue Next Year | N/A | $4.48 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ 3.53 |
| 52 Week Low | $1.66 | $0.56 |
| 52 Week High | $11.88 | $3.37 |
Technical Indicators
Market Signals| Indicator | KLRS | FLL |
|---|---|---|
| Relative Strength Index (RSI) | 30.69 | 23.82 |
| Support Level | N/A | N/A |
| Resistance Level | $2.66 | $1.19 |
| Average True Range (ATR) | 0.22 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 0.00 | 1.24 |
Price Performance
Historical ComparisonAbout KLRS Kalaris Therapeutics Inc.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
About FLL Full House Resorts Inc.
Full House Resorts Inc owns, operates, develops, manages, and invests in casinos and related hospitality and entertainment facilities. It offers facilities related to gaming, hotel, dining, entertainment, retail, and other amenities. The group's reportable segments are Midwest & South, West, and Contracted Sports Wagering, It generates the majority of its revenue from the Midwest & South segment which includes Silver Slipper Casino and Hotel, Rising Star Casino Resort, and American Place. The west segment includes Grand Lodge, Stockman's Casino, Bronco Billy's Casino and Hotel, and Chamonix Casino Hotel. The Contracted Sports Wagering segment comprises on-site and online sports wagering skins. Geographically, it operates in United States.